The research team led by Daniel Anderson at the Massachusetts Institute of Technology has published a research paper titled “Combinatorial development of nebulized mRNA delivery formulations for the lungs” in the journalRead More…
In recent years, messenger ribonucleic acid (mRNA) therapy has garnered significant interest and has been developed for the treatment of a range of diseases, including rare genetic disorders, neurodegenerative diseases, inflammation, cancer,Read More…
Lyme disease is the most common vector-borne infectious disease in the United States, in part because there is currently no human vaccine against it. In a recent research report titled “Development ofRead More…
International pharmaceutical giant Sanofi recently announced a $25 million investment over five years in MIT’s Daniel Anderson lab to support the development of next-generation mRNA delivery technology. The funding will be utilizedRead More…
The mRNA COVID-19 vaccine plays a key role in the fight against COVID-19. Because of its rapid production ability and promising results in a number of clinical studies, vaccines and treatments basedRead More…
At the 2022 annual meeting of the American Association for Cancer Research (AACR), BioNTech released its phase 1 clinical data of CAR-T + CARVac in the treatment of Claudin6 (CLDN6) positive solidRead More…
With the rapid development of tumor immunotherapy, drugs have been approved at PD-1, CTLA-4, PD-L1, LAG-3 and other immune checkpoints, bringing a lot of enthusiasm for research and development to the industry.Read More…
As the mRNA vaccine has achieved great results in the prevention of COVID-19, it has been widely recognized by global researchers. At the same time, the application prospect of mRNA technology inRead More…